[Comment] Overall survival assessment in cancer drug trials: a luxury or a necessity?

In August, 2025, the US Food and Drug Administration (FDA) published a draft guidance on the assessment of overall survival in randomised cancer drug trials.1 In essence, the guidance states that overall survival and quality of life are the only clinical endpoints to confirm the benefit of any cancer therapies—ultimately, patients want longer and better lives as a trade-off for…